TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Stockholm Exchange: EPCT) announced today that the Swedish AML Group which comprises the leading hematology experts in Sweden has included Ceplene® (histamine dihydrochloride) in its Guidelines entitled “National Guidelines for Diagnosis and Treatment of Acute Myeloid Leukemia in Adults.” These guidelines, which were issued earlier this month, recommend for the first time the inclusion of Ceplene for AML remission maintenance therapy. Ceplene plus low-dose interleukin (IL-2) is indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission by the European Medicines Evaluation Agency (EMEA).
